Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 19/20 | 0.67 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012085 | 0.88 | AKR1C3 (0.73) | AKR1C3AKR1C1MEN1KMT2A | |
| SCHEMBL3284957 | 0.85 | AKR1C3 (0.73) | AKR1C3AKR1C1 | |
| SCHEMBL3280649 | 0.84 | AKR1C3 (0.76) | AKR1C3AKR1C1MEN1KMT2A | |
| SCHEMBL3282044 | 0.83 | AKR1C3 (0.73) | AKR1C3AKR1C1 | |
| SCHEMBL3281383 | 0.83 | AKR1C3 (0.69) | AKR1C3AKR1C1 | |
| SCHEMBL3287776 | 0.82 | AKR1C3 (0.66) | AKR1C3AKR1C1 | |
| SCHEMBL3282023 | 0.82 | HDAC6 (0.71) | AKR1C3AKR1C1 | |
| SCHEMBL3286988 | 0.82 | AKR1C3 (0.73) | AKR1C3AKR1C1MEN1KMT2A | |
| SCHEMBL3284893 | 0.81 | AKR1C3 (0.71) | AKR1C3AKR1C1 | |
| SCHEMBL3282211 | 0.80 | AKR1C3 (0.77) | AKR1C3AKR1C1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | AKR1C3 1345/4885AKR1C1 1295/4885MEN1 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.